Verastem Inc (VSTM)

Nov 16, 2024

Data-Based Insights About Verastem Inc (VSTM) - Stocks Register

Nov 16, 2024

Nov 15, 2024

OrbiMed Advisors LLC's Strategic Acquisition of Verastem Inc Sha - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Alyeska Investment Group L.P.'s Strategic Acquisition of Veraste - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Nov 15, 2024

Nov 15, 2024

Verastem, Inc. (NASDAQ:VSTM) Receives $14.57 Average PT from Analysts - MarketBeat

Nov 15, 2024

Nov 14, 2024

Verastem's SWOT analysis: oncology firm's stock faces pivotal FDA decision - Investing.com India

Nov 14, 2024

Nov 14, 2024

Verastem's SWOT analysis: oncology firm's stock faces pivotal FDA decision By Investing.com - Investing.com Canada

Nov 14, 2024

Nov 13, 2024

Stonepine Capital Management, LLC Increases Stake in Verastem Inc - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

Such Is The Power Of Verastem Inc (NASDAQ: VSTM) - Stocks Register

Nov 13, 2024

Nov 09, 2024

Verastem (NASDAQ:VSTM) Stock Rating Lowered by StockNews.com - Defense World

Nov 09, 2024

Nov 07, 2024

Verastem CEO Paterson sells $3,118 in common stock - Investing.com

Nov 07, 2024

Nov 07, 2024

Verastem CEO Paterson sells $3,118 in common stock By Investing.com - Investing.com UK

Nov 07, 2024

Nov 07, 2024

Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates - BioSpace

Nov 07, 2024

Nov 07, 2024

Verastem: Q3 Earnings Snapshot - The Washington Post

Nov 07, 2024

Nov 06, 2024

Verastem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 06, 2024

Nov 04, 2024

Chugai PharmaceuticalVerastem Oncology's Announcement Regarding Avutometinib - Marketscreener.com

Nov 04, 2024

Nov 02, 2024

Avutometinib With Defactinib for Recurrent KRAS Mutant LGSOC Completes Rolling New Drug Application - Pharmacy Times

Nov 02, 2024

Nov 01, 2024

Verastem Oncology submits NDA for ovarian cancer treatment - Yahoo Finance

Nov 01, 2024

Nov 01, 2024

Verastem (FRA:2VSA) Owner Earnings per Share (TTM) : -3.30 (As of Jun. 2024) - GuruFocus.com

Nov 01, 2024

Oct 31, 2024

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - StockTitan

Oct 31, 2024

Oct 31, 2024

Verastem Oncology to Participate in Upcoming Investor Conferences - BioSpace

Oct 31, 2024

Oct 30, 2024

SG Americas Securities LLC Purchases New Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World

Oct 30, 2024

Oct 24, 2024

Verastem's SWOT analysis: ovarian cancer drug maker's stock faces pivotal year - Investing.com India

Oct 24, 2024

Oct 21, 2024

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Oct 21, 2024

Oct 18, 2024

Verastem preps an NDA as the stock struggles - BioWorld Online

Oct 18, 2024

Oct 18, 2024

Verastem's (VSTM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Oct 18, 2024

Oct 18, 2024

Verastem Holders Endure Difficult Day, Analysts Holding Firm (VSTM) - AskTraders

Oct 18, 2024

Oct 17, 2024

Truist keeps $15 target on Verastem amid sell-off By Investing.com - Investing.com UK

Oct 17, 2024

Oct 17, 2024

Verastem Advances Cancer Treatment with Promising Trial Results - TipRanks

Oct 17, 2024

Oct 17, 2024

Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting - StockTitan

Oct 17, 2024

Oct 15, 2024

This trade activity should not be overlooked: Verastem Inc (VSTM) - SETE News

Oct 15, 2024

Oct 14, 2024

Verastem Inc (VSTM) stock: A year of ups and downs - US Post News

Oct 14, 2024

Oct 10, 2024

Verastem CFO sells shares worth $17 to cover tax obligations By Investing.com - Investing.com Canada

Oct 10, 2024

Oct 09, 2024

Verastem CFO sells shares worth $17 to cover tax obligations - Investing.com India

Oct 09, 2024

Oct 09, 2024

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting - StockTitan

Oct 09, 2024

Oct 07, 2024

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Oct 07, 2024

Oct 05, 2024

Verastem whipsaws after updates for cancer drug combo - MSN

Oct 05, 2024

Oct 03, 2024

Taking the lead: Verastem Inc (VSTM) - SETE News

Oct 03, 2024

Oct 02, 2024

Guggenheim’s latest rating for VSTM stock - Knox Daily

Oct 02, 2024

Oct 02, 2024

Verastem Inc’s results are impressive - US Post News

Oct 02, 2024

Oct 01, 2024

Nantahala Capital Management LLC Purchases Shares of 400,000 Verastem, Inc. (NASDAQ:VSTM) - Defense World

Oct 01, 2024

Oct 01, 2024

Verastem Inc (VSTM) Stock: A Year of Decreases and Increases - The InvestChronicle

Oct 01, 2024

Oct 01, 2024

Guggenheim Initiates Coverage of Verastem (VSTM) with Buy Recommendation - Nasdaq

Oct 01, 2024

Oct 01, 2024

Nantahala Capital Management LLC Takes Position in Verastem, Inc. (NASDAQ:VSTM) - MarketBeat

Oct 01, 2024